Nada Elbuluk, MD, a board certified dermatologist at the University of Southern California in Los Angeles, California, discusses the importance of offering a variety of treatment options to patients with vitiligo and tailoring these treatments to a patient’s specific needs.
Dr. Del Rosso, JCAD’s Clinical Editor-in-Chief, reviews a poster presented by Volkova et al at the 2024 American Academy of Dermatology annual meeting. The poster presented findings from the TRuE-V long-term extension (LTE) study, which evaluated changes in serum biomarkers in patients with segmental vitiligo who were randomized in the LTE to apply the vehicle or continue using ruxolitinib 1.5% cream after both groups had used ruxolitinib cream in the parent studies....